ADC Therapeutics Q3 2023 Earnings Report

ADC Therapeutics EPS Results

• Actual EPS: -$0.58
• Consensus EPS: -$0.61
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: N/A

ADC Therapeutics Revenue Results

• Actual Revenue: $14.49 million
• Expected Revenue: $14.57 million
• Beat/Miss: Missed by -$80.00 thousand
• YoY Revenue Growth: N/A

ADC Therapeutics Announcement Details

• Quarter: Q3 2023
• Date: 11/7/2023
• Time: N/A

ADC Therapeutics (NYSE:ADCT) focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.